Seminars in Hematology
Volume 37, Issue 1 , Pages 102-109 , January 2000

Cyclophosphamide and other new agents for the treatment of severe aplastic anemia

  • John F Tisdale

      Affiliations

    • Corresponding Author InformationAddress reprint requests to John F. Tisdale, MD, Bldg 10, Room 9N116, Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.
    • From the Molecular and Clinical Hematology Branch, National Insitute of Diabetes and Digestive and Kidney Diseases, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    • From the Division of Hematology, University of Utah, Salt Lake City, UT, USA
    • ,
  • Daniel E Dunn

      Affiliations

    • From the Molecular and Clinical Hematology Branch, National Insitute of Diabetes and Digestive and Kidney Diseases, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    • From the Division of Hematology, University of Utah, Salt Lake City, UT, USA
    • ,
  • Jaroslaw Maciejewski

      Affiliations

    • From the Molecular and Clinical Hematology Branch, National Insitute of Diabetes and Digestive and Kidney Diseases, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    • From the Division of Hematology, University of Utah, Salt Lake City, UT, USA

References 

  1. Appelbaum FR, Fefer A, Cheever MA, et al.  Treatment of aplastic anemia by bone marrow transplantation in identical twins. Blood. 1980;55:1033–1039
  2. Bacigalupo A, Broccia G, Corda G, et al.  Antilymphocyte globulin, cydosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA working party. Blood. 1995;85:1348–1353
  3. Baran DT, Griner PF, Klemperer MR. Recovery from aplastic anemia after treatment with cyclophosphamide. N Engl J Med. 1976;295:1522–1523
  4. Berenbaum MC. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature. 1963;200:84
  5. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation. 1995;59:1194–1200
  6. Brinkman CJJ, Nillesen WM, Hommes OR. T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: Effects of cyclophosphamide. Clin Immunol Immunopathol. 1983;29:341–348
  7. Brinkman CJJ, Nillsen WM, Hommes OR. The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressvie multiple sclerosis. Acta Neurol Scand. 1984;69:90–96
  8. Brodsky RA, Petri M, Smith BD, et al.  Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med. 1998;129:1031–1035
  9. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood. 1996;87:491–494
  10. Cai W, Hu L, Foulkes JG. Transcription-modulating drugs: Mechanism and selectivity. Curr Opin Biotech. 1996;7:608–615
  11. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia. N Engl J Med. 1983;308:113–118
  12. Champlin R, Ho W, Bayever E, et al.  Treatment of aplastic anemia: Results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T cell antibody. In:  Young NS,  Levine AS,  Humphries RK editor. Aplastic Anemia: Stem Cell Biology and Advances in Treatment. New York, NY: Liss; 1984;p. 227–238
  13. Chiorazzi N, Fox DA, Katz DH. Hapten-speific IgE antibody responses in mice VI. Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide. J Immunol. 1976;117:1629–1637
  14. Chiorazzi N, Fox DA, Katz DH. Hapten-specific IgE antibody responses in mice VII. Conversion of IgE non-responder strains to IgE responders by elimination of suppressor T cell activity. J Immunol. 1977;118:48–54
  15. Clements PJ, Davis J. Cytotoxic drugs: Their clinical application to the rheumatic diseases. In: Semin Arthritis Rheum. 15:1986;p. 231–254
  16. DeVita S, Neri R, Bombardieri S. Cyclophosphamide pulses in the treatment of rheumatic diseases: An update. Clin Exp Rheumatol. 1991;9:179–193
  17. Doney K, Martin P, Storb R, et al.  A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol. 1985;13:520–524
  18. Doney K, Pepe M, Storb R, et al.  Immunosuppressive therapy of aplastic anemia: Results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. Blood. 1992;79:2566–2571
  19. Dunn DE, Tanawattanacharoen P, Boccuni P, et al.  Paroxymal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401–408
  20. Ferguson RM, Simmons RL. Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors. Transplantation. 1978;25:36–38
  21. Fischer D. Alkylating agents. In:  Fischer DS,  Marsh J editor. Cancer Therapy. Boston, MA: Hall Medical; 1982;
  22. Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am. 1994;20:265–299
  23. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–1304
  24. Genestier L, Fournel S, Flacher M, et al.  Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood. 1998;91:2360–2368
  25. Hinterberger-Fischer M, Hocker P, Lechner K, et al.  Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure. Eur J Haematol. 1989;43:136–142
  26. Horigome A, Hirano T, Oka K, et al.  Glucocorticoids and cyclosporine induce apoptosis in mitogen-activated human peripheral mononuclear cells. Immunopharmacology. 1997;27:87–94
  27. Jansen J, Gratama JW, Zwaan FE, et al.  Therapy with monoclonal antibody OKT3 in severe aplastic anemia. Exp Hematol. 1984;12(suppl 15):46–47
  28. Kaufman DB, Leventhal JR, Stuart J, et al.  Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: Initial experience in 50 consecutive cases. Transplantation. 1999;67:586–593
  29. Kelly PA, Gruber SA, Behbod F, et al.  Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy. 1997;17:1148–1156
  30. Kovarik JM, Rawlings E, Sweny P, et al.  Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody ZDZ CHI 621 in renal allograft recipients. Transplant Int. 1996;1:32–33 (suppl)
  31. Leonard EM, Raefsky E, Griffith P, et al.  Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989;72:278–284
  32. Maciejewski J, Selleri C, Anderson S, et al.  Fas antigen expression on CD34+ human marrow cells is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183–3190
  33. Maciejewski JP, Hibbs JR, Anderson S, et al.  Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol. 1994;22:1102–1110
  34. Maciejewski JP, Selleri C, Sato T, et al.  Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. Br J Haematol. 1995;91:245–252
  35. McCune WJ, Fox D. Intravenous cyclophoshamide therapy of severe SLE. Rheum Dis Clin North Am. 1989;15:455–477
  36. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation. 1998;65:1481–1489
  37. Mickey MR, Ellison GW, Fahey JL. Correlation of clinical and immunologic states in multiple sclerosis. Arch Neurol. 1987;44:371–375
  38. Moody DJ, Kagan J, Liao D. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients effects of long-term treatment on immunologic parameters. J Neuroimmunol. 1987;14:161–173
  39. Nashan B, Moore R, Amlot P, et al.  Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal transplant recipients. CHIB 201 International Study Group. Lancet. 1997;350:1193–1198
  40. Nimer SD, Ireland P, Meshkinpour A, et al.  An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 1994;84:923–927
  41. Oram RH, Mills AE, Thomas JEP. Primary aplastic anaemia in pregnancy. S Afr Med J. 1972;46:1738–1740
  42. Panceri R, Fraschini D, Tornotti G, et al.  Successful use of high-dose cyclophosphamide in a child with severe autoimmune hemolytic anemia. Haematologica. 1992;77:76–78
  43. Poulter LW, Turk JL. Proportional increase in the Φ-carrying lymphocytes in peripheral lymphoid tissue following treatment with cyclophosphamide. Nature New Biol. 1972;238:17–18
  44. Platanias L, Gascon P, Bielory L, et al.  Lymphocyte phenotype and lymphokines following anti-thymocyte globulin therapy in patients with aplastic anaemia. Br J Haematol. 1987;66:437–443
  45. Rebellato LM, Gross U, Verbanac KM, et al.  A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation. 1994;57:685–694
  46. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351–358
  47. Rolinghoff M, Starzinski-Powitz A, Pfizenmaier K. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med. 1977;145:455–459
  48. Rosenfeld SJ, Kimball J, Vining D, et al.  Intensive immuno-suppresion with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058–3065
  49. Schrezenmeier H, Marin P, Raghavachar A, et al.  Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol. 1993;85:371–377
  50. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335–340
  51. Selleri C, Maciejewski JP, Sato T, et al.  Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 1996;87:4149–4157
  52. Selleri C, Sato T, Anderson S, et al.  Interferon—gamma and tumor necrosis factor-α suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165:538–546
  53. Sensenbrenner LL, Steele AA, Santos GW. Recovery of hematologic competence without engraftment following attempted bone marrow transplantation for aplastic anemia: Report of a case with diffusion chamber studies. Exp Hematol. 1977;5:51–58
  54. Shapiro R, Jordan ML, Scandebury VP, et al.  A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999;67:411–415
  55. Sievers TM, Rossi SJ, Ghobrial RM, et al.  Mycophenolate mofetil. Pharmacotherapy. 1997;17:1178–1197
  56. Sihvola M, Hurme M. The origin of cytotoxic T lymphocyte precursors (CTL-P): MHC-restricted and alloreactive CTL-P in the spleen during regeneration after a sublethal dose of cyclophosphamide (Cy). Immunology. 1983;130:1077–1083
  57. Sihvola M, Hurme M. Defective repertoire of proliferative T cells during lymphatic regeneration. Immunology. 1984;51:313–318
  58. Sloand E, Kim S, Maciejewski JP, et al.  Presence of intracellular interferon-gamma (IFN-gamma) in circulating lymphocytes and response to immunosuppressive therapy in patients with aplastic anemia. Blood. 1998;10(suppl 1):158a; abstr
  59. Socié G, Henry-Amar M, Bacigalupo A, et al.  Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 1993;329:1152–1157
  60. Speck B, Cornu P, Jeannet M, et al.  Autologous marrow recovery following allogeneic marrow transplantation in a patient with severe aplastic anemia. Exp Hematol. 1976;4:131–137
  61. Taniguchi T, Manami Y. The IL-2/IL-2 receptor system: A current overview. Cell. 1993;73:5–8
  62. Taniguchi Y, Frickhofen N, Raghavachar A, et al.  Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. Eur J Haematol. 1990;44:244–251
  63. Taylor HG, Samantha A. Treatment of vasculitis. Br J Clin Pharmacol. 1993;35:93–104
  64. ten Berge RJM, van Walbeek HK, Schellekens PTA. Evaluation of the immunosuppressive effects of cyclophoshamide in patients with multiple sclerosis. Clin Exp Immunol. 1982;50:495–502
  65. Teramura M, Kobayashi S, Iwabe K, et al.  Mechanism of action of annthymocyte globulin in the treatment of aplastic anaemia: In vitro evidence for the presence of immunosuppressive mechanism. Br J Haematol. 1997;96:80–84
  66. Territo MC. Autologous bone marrow repopulation following high dose cyclophosphamide and allogeneic marrow transplantation in aplastic anemia. Br J Haematol. 1977;36:305–311
  67. Thomas ED, Storb R, Fefer A, et al.  Aplastic anaemia treated by marrow transplantation. Lancet. 1972;1:284–289
  68. Thomas ED, Storb R, Giblett ER, et al.  Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol. 1976;4:97–102
  69. Tichelli A, Gratwohl A, Würsch A, et al.  Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988;69:413–418
  70. Turk JL, Poulter LW. Selective depletion of lymphoid tissue by cyclophoshamide. Clin Exp Immunol. 1972;10:285–296
  71. Valente RM, Conn DL. Current therapies for systemic vasculitis. In: Semin Neurol. 14:1994;p. 380–386
  72. Varilka K, Hurme J. The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: Inhibition of helper T-cell induction in vitro. Immunology. 1983;48:433–438
  73. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc. 1998;30:2155–2158
  74. Walker CM, Paetkau V, Rawls WE. Abrogation of antipichinde virus cytotoxic T cell memory by cyclophosphamide and restoration by coinfection or interleukin-2. J Immunol. 1985;135:1401–1407
  75. Winklestein A. Effect of immunosuppressive drugs on T and B lymphocytes in guinea pigs. Blood. 1977;50:81–91
  76. Young N, Griffith P, Brittain E, et al.  A multicenter trial of anti-thymocyte globulin in aplastic anemia and related diseases. Blood. 1988;72:1861–1869
  77. Young NS. Definitive treatment of acquired aplastic anemia. In:  Young NS,  Alter BP editor. Aplastic Anemia, Acquired and Inherited. Philadelphia, PA: Saunders; 1994;p. 159–200
  78. Young NS, Alter BP. Aplastic Anemia, Acquired and Inherited. Philadelphia, PA: Saunders; 1994;
  79. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367–3377

☆ This is a US government work. There are no restrictions to its use.

PII: S0037-1963(00)90034-9

Seminars in Hematology
Volume 37, Issue 1 , Pages 102-109 , January 2000

Article Tools